share_log

瑞银:首予上海医药“买入”评级 目标价14.9港元

UBS: Target price of HK$14.9 for the initial “buy” rating for Shanghai pharmaceuticals

新浪港股 ·  Apr 17 03:48

UBS released a research report stating that it initially gave Shanghai Pharmaceuticals (02607) a “buy” rating, with a target price of HK$14.9. Shanghai Pharmaceutical is the second-largest pharmaceutical distributor in China. It accounts for about 9.5% of the market share in 2022. It is optimistic that it has the potential to have differentiated one-stop distribution services and its own pipeline for the production of new drugs. It is predicted that the compound annual growth rate of revenue and profit will reach 10% and 10.6% from 2024 to 2026. Potential positive catalysts include approval of new drugs, strong drug sales expectations, and signing new exclusive distribution agreements with international pharmaceutical companies.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment